摘要
目的:探讨瑞舒伐他汀对冠心病患者心功能、血脂水平的影响。方法:选取2017年1月至2017年12月喀什地区第一人民医院收治的冠心病患者126例,按照随机数字表法分成观察组和对照组,每组63例。对照组患者给予常规对症治疗,观察组患者在对照组的基础上加用瑞舒伐他汀治疗。治疗2个月后,比较两组患者的心功能[左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)及左心室射血分数(LVEF)]、血脂水平[低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)及三酰甘油(TG)]的差异。结果:治疗后,两组患者的LVESV、LVEDV均明显低于治疗前,LVEF明显高于治疗前;且观察组患者的LVESV、LVEDV明显低于对照组,LVEF明显高于对照组,上述差异均有统计学意义(P<0.05)。治疗后,两组患者的LDL-C、TC及TG水平明显低于治疗前,HDL-C水平明显高于治疗前;且观察组患者的LDL-C、TC及TG水平明显低于对照组,HDL-C水平明显高于对照组,上述差异均有统计学意义(P<0.05)。结论:瑞舒伐他汀能够显著改善冠心病患者的心功能与血脂水平,有利于控制疾病的进展。
OBJECTIVE： To probe into the effects of rosuvastatin on cardiac function and blood lipid level in patients with coronary heart disease. METHODS： 126 patients with coronary heart disease admitted into the First People＇s Hospital of Kashi Region from Jan. 2017 to Dec. 2017 were extracted to be divided into observation group and control group via the random number table,with 63 cases in each. The control group was given conventional symptomatic treatment,while the observation group additionally received rosuvastatin based on the control group. After treatment of 2 months,differences of cardiac function [left ventricular end-diastolic volume（ LVEDV）,left ventricular end-systolic volume（ LVESV）,left ventricular ejection fraction（ LVEF） ],lipid levels [low density lipoprotein cholesterol（ LDL-C）,high density lipoprotein cholesterol（ HDL-C）,total cholesterol（ TC） and triacylglycerol（ TG） ]of two groups were compared. RESULTS： After treatment,the levels of LVESV,LVEDV of two groups decreased significantly compared with before treatment,and the levels of LVEF increased significantly compared with before treatment; and the levels of LVESV,LVEDV in observation group were significantly lower than those in control group,and LVEF of observation group was significantly higher than that of control group,with statistically significant differences（ P〈0. 05）. After treatment,the levels of LDL-C,TC and TG in two groups were significantly lower than those before treatment,and HDL-C was significantly higher than that before treatment. The levels of LDL-C,TC and TG in observation group were significantly lower than those in control group,and HDL-C of observation group was significantly higher than that of control group,with statistically significant differences（ P〈0. 05）. CONCLUSIONS：Rosuvastatin can significantly improve the heart function and blood lipid level of patients with coronary heart disease,and help to control the progression of disease.
作者
阿地力.沙吾提
米娜瓦尔.阿不都克力木
Adili· SHAWUTI;Minavaer· ABUDUKELIMU(Dept.of Coronary Heart Disease,the First People＇s Hospital of Kashi Region,Xinjiang Kashi 844000,China;Dept.of Pacing Electrophysiology,the First People＇s Hospital of Kashi Region,Xinjiang Kashi 844000,China)
出处
《中国医院用药评价与分析》
2018年第9期1188-1189,1192,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
瑞舒伐他汀
冠心病
心功能
血脂水平
Rosuvastatin
Coronary heart disease
Cardiac function
Blood lipid level
